138 related articles for article (PubMed ID: 36282671)
21. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
[TBL] [Abstract][Full Text] [Related]
22. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients.
Jew S; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Spektor TM; Berenson JR
Br J Haematol; 2021 Mar; 192(6):1064-1067. PubMed ID: 32321191
[TBL] [Abstract][Full Text] [Related]
23. Analytical assessment and validation of the ProteinSimple ELLA serum B-cell maturation antigen assay.
Kirchhoff DC; Zhang W; Chandras A; Mendu DR
Pract Lab Med; 2024 Jan; 38():e00354. PubMed ID: 38283321
[TBL] [Abstract][Full Text] [Related]
24. Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.
Springer C; Krauter J; Trummer A
Oncotarget; 2023 Dec; 14():949-956. PubMed ID: 38039414
[TBL] [Abstract][Full Text] [Related]
25. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
26. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.
Nobari ST; Nojadeh JN; Talebi M
J Transl Med; 2022 Feb; 20(1):82. PubMed ID: 35144648
[TBL] [Abstract][Full Text] [Related]
27. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
Bellucci R; Alyea EP; Chiaretti S; Wu CJ; Zorn E; Weller E; Wu B; Canning C; Schlossman R; Munshi NC; Anderson KC; Ritz J
Blood; 2005 May; 105(10):3945-50. PubMed ID: 15692072
[TBL] [Abstract][Full Text] [Related]
28. Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia.
Soof CM; Spektor TM; Parikh SA; Slager SL; Rabe KG; Call TG; Kenderian SS; Ding W; Muchtar E; Ghermezi M; Kay NE; Berenson JR
Exp Hematol; 2022 Jul; 111():32-40. PubMed ID: 35525334
[TBL] [Abstract][Full Text] [Related]
29. Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma.
Ma T; Shi J; Xiao Y; Bian T; Wang J; Hui L; Wang M; Liu H
Front Immunol; 2021; 12():724411. PubMed ID: 34867949
[TBL] [Abstract][Full Text] [Related]
30. [The expression level of secretory mature B cell surface antigen in primary diagnosed multiple myeloma and its clinical significance].
Yan Z; Chen GH; Yao WQ; Yan LZ; Jin S; Shang JJ; Shi XL; Wu DP; Fu CC
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2351-2356. PubMed ID: 35970793
[No Abstract] [Full Text] [Related]
31. Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma.
Miao YR; Thakkar K; Cenik C; Jiang D; Mizuno K; Jia C; Li CG; Zhao H; Diep A; Xu Y; Zhang XE; Yang TTC; Liedtke M; Abidi P; Leung WS; Koong AC; Giaccia AJ
J Exp Med; 2022 Sep; 219(9):. PubMed ID: 35881112
[TBL] [Abstract][Full Text] [Related]
32. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
[TBL] [Abstract][Full Text] [Related]
33. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement.
Schuh E; Musumeci A; Thaler FS; Laurent S; Ellwart JW; Hohlfeld R; Krug A; Meinl E
J Immunol; 2017 Apr; 198(8):3081-3088. PubMed ID: 28283566
[TBL] [Abstract][Full Text] [Related]
34. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
35. Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.
Li D; Que Y; Ding S; Hu G; Wang W; Mao X; Wang Y; Li C; Huang L; Zhou J; Zhang W; Xiao M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36137648
[TBL] [Abstract][Full Text] [Related]
36. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
37. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma.
Salem DA; Maric I; Yuan CM; Liewehr DJ; Venzon DJ; Kochenderfer J; Stetler-Stevenson M
Leuk Res; 2018 Aug; 71():106-111. PubMed ID: 30053652
[TBL] [Abstract][Full Text] [Related]
38. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
39. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker.
Sanchez E; Tanenbaum EJ; Patil S; Li M; Soof CM; Vidisheva A; Waterman GN; Hekmati T; Tang G; Wang CS; Chen H; Berenson J
Expert Rev Mol Diagn; 2018 Apr; 18(4):319-329. PubMed ID: 29504446
[TBL] [Abstract][Full Text] [Related]
40. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
Sanchez E; Li M; Kitto A; Li J; Wang CS; Kirk DT; Yellin O; Nichols CM; Dreyer MP; Ahles CP; Robinson A; Madden E; Waterman GN; Swift RA; Bonavida B; Boccia R; Vescio RA; Crowley J; Chen H; Berenson JR
Br J Haematol; 2012 Sep; 158(6):727-38. PubMed ID: 22804669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
